Following Nature's Rules
Researchers develop new methods for treating degenerative neurological disease.
University of Arizona researchers have developed a new class of drugs that is able to cross the blood-brain barrier and could be used to treat degenerative neurological diseases and conditions.
“Francis Bacon said it best when he wrote, ‘Nature, to be commanded, must be obeyed,’” says Robin Polt, co-inventor of the new drug technology and a professor in the department of chemistry and biochemistry in the UArizona College of Science. “We’re taking nature’s own tools and using them to design drugs.”
Neurological disorders are the leading cause of disability and the second-leading cause of death worldwide. Traumatic brain injuries and brain disorders like Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and stroke affect over 8 million people in the United States each year and have limited effective treatments.
One reason for the lack of treatments is the body’s innate defense mechanism: The brain is protected by a natural barrier. This blockade consists of a network of blood vessels and tissues made up of cells that help keep harmful substances from entering the brain while allowing essentials like water, oxygen and carbon dioxide to pass through. Because the brain requires a large amount of energy to function, the barrier also allows sugars and other carbohydrates through, and some compounds that block pain, such as anesthetics and endorphins, can get through the barrier as well.
The challenge is that the blood-brain barrier keeps out compounds naturally produced by the body that can be used to treat neurological disorders. Researchers have been trying to find ways to alter these compounds so that they can get through the barrier.
Polt and his UArizona collaborators say the key to their innovation lies in a specific type of peptide called a glycopeptide, which is made up of amino acids that have carbohydrate groups attached to them. The researchers focused on taking naturally occurring chemical messengers that carry signals between neurons — called endogenous neurotransmitters — and converting them into drugs by attaching carbohydrates to them to produce glycopeptides. In doing so, they can change how these molecules interact with and pass through the blood-brain barrier.
An important aspect of this new class of drugs is that they are metabolized into nontoxic amino acids and sugars in the body. This is different from traditional drugs, which can form toxins when the body breaks them down.
With this technology, the researchers demonstrated that they can now reach previously inaccessible receptor targets in the brain. The original research that gave rise to the drug design was funded by the National Institutes of Health and the National Institute of Neurological Disorders and Stroke. UArizona has now licensed the technology to the researchers’ startup, Teleport Pharmaceuticals, through Tech Launch Arizona (TLA), the university office that commercializes inventions stemming from UArizona research and innovation.
“We’re excited about what we’re doing now, but we’re looking at hundreds of other peptides that the brain produces that are opening more and more possibilities,” says Polt, a BIO5 Institute member who also has faculty appointments in the R. Ken Coit College of Pharmacy’s Department of Pharmacology and Toxicology and the College of Science’s Department of Neuroscience. “In looking at these glycopeptides, we’re opening doors that would otherwise be closed.”
In addition to Polt, the inventing team includes Michael Heien, an associate professor in the department of chemistry and biochemistry; Torsten Falk, an associate professor in the department of neurology; and John Streicher, an associate professor in the College of Medicine – Tucson’s Department of Pharmacology.
“Robin and his collaborators have been a prolific, entrepreneurial team for many years,” says Bruce Burgess, TLA’s director of new ventures. “It’s wonderful to see a group with such a focus on creating impact from their research engaged and launching a company to bring their discoveries to bear on patients’ lives.”